SCHEMBL1474441

SCHEMBL1474441

COc1cccc(-c2cc(C(=O)NCCc3ccncc3)no2)c1

nearest known ligand 0.75

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.75
RAB9A P51151 7/20 0.73
NPC1 O15118 6/20 0.73
HPGD P15428 5/20 0.73
SMN1; SMN2 Q16637 5/20 0.73
TP53 P04637 4/20 0.73
CYP1A2 P05177 1/20 0.73
CYP2C19 P33261 1/20 0.73
LMNA P02545 1/20 0.65
KMT2A Q03164 3/20 0.64
MEN1 O00255 2/20 0.64
ALDH1A1 P00352 5/20 0.62
HSD17B10 Q99714 1/20 0.62
POLB P06746 1/20 0.59
FAAH O00519 1/20 0.59
KDM4E B2RXH2 1/20 0.59
MAPK1 P28482 1/20 0.59
TSHR P16473 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1475291 0.88 NPC1 (0.71) MAPTRAB9ANPC1HPGDSMN1; SMN2
SCHEMBL15190092 0.85 MAPT (0.55) MAPTRAB9ANPC1HPGDSMN1; SMN2
SCHEMBL1474945 0.85 MAPT (0.64) MAPTRAB9ANPC1HPGDSMN1; SMN2
SCHEMBL1474935 0.84 FAAH (0.81) MAPTRAB9ANPC1HPGDSMN1; SMN2
SCHEMBL1474724 0.84 MAPT (0.63) MAPTRAB9ANPC1HPGDSMN1; SMN2
SCHEMBL1476073 0.84 MAPT (0.63) MAPTRAB9ANPC1HPGDSMN1; SMN2
SCHEMBL1474570 0.81 FAAH (0.62) MAPTRAB9ANPC1HPGDSMN1; SMN2
SCHEMBL1476525 0.80 MAPT (0.59) MAPTRAB9ANPC1HPGDSMN1; SMN2
SCHEMBL1474695 0.80 MAPT (0.86) MAPTRAB9ANPC1HPGDSMN1; SMN2
SCHEMBL1475213 0.79 ALDH1A1 (0.74) MAPTRAB9ANPC1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 MAPT 2497/4885RAB9A 2013/4885NPC1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.